Background Previously, the only available glucagon-like peptide-1 receptor agonists (GLP-1
RA) were injectable. Approval of oral semaglutide (Rybelsus®) represents the first orally …

Objective: The purpose of this article is to review the pharmacological characteristics and
clinical evidence of oral semaglutide for the treatment of type 2 diabetes mellitus (T2DM) …

Purpose To provide pharmacists with information on counseling patients with type 2
diabetes (T2D) receiving oral semaglutide. Summary Oral semaglutide, the first oral …

Aim Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA)
indicated for glycaemic management in adults with type 2 diabetes (T2D). Oral semaglutide …

Objectives To investigate the efficacy and safety of oral semaglutide 7 and 14 mg, the only
orally delivered glucagon-like peptide-1 (GLP-1) receptor agonist tablet approved for type 2 …

Background Oral semaglutide is a novel tablet containing the human glucagon-like peptide-
1 (GLP‑1) analogue semaglutide, co-formulated with the absorption enhancer sodium N-(8 …

Aims To assess the efficacy and safety of semaglutide, a recently approved glucagon‐like
peptide 1 receptor agonist (GLP‐1 RA) for type 2 diabetes. Materials and methods We …

ABSTRACT Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists are highly
potent antihyperglycemic drugs that impose low risk of hypoglycemia and also result in body …

Objectives To evaluate the efficacy and safety of the glucagon-like peptide-1 (GLP-1)
receptor agonist (RA) oral semaglutide in the treatment of type 2 diabetes mellitus (T2DM) …

The first tablet formulation of a glucagon-like peptide-1 receptor agonist (GLP-1RA), oral
semaglutide, was approved in September 2019 for the treatment of adults with type 2 …